ArticleThoracic cancer2019
Primary malignant melanoma of the esophagus: A retrospective analysis of clinical features, management, and survival of 76 patients.
Article in Thoracic cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 42 citations in OpenAlex.
- Case Report: Locally advanced primary esophageal melanoma with early brain metastasis.Frontiers in oncology · 2026Article
- Primary Malignant Melanoma of the Oesophagus Treated With Immunotherapy: A Case Report and Scoping Review of the Literature.Journal of gastrointestinal cancer · 2025Article
- Surgical management of oligometastatic recurrence in primary esophageal melanoma: a feasible approach in resource-limited settings.Journal of surgical case reports · 2025Article
- The first case of primary malignant melanoma of the esophagus to achieve pathologic complete response after preoperative ipilimumab + nivolumab followed by resection.Clinical journal of gastroenterology · 2025Article
- Promising Treatment Strategy for Primary Malignant Melanoma of the Esophagus by Radical Esophagectomy and Nivolumab as Adjuvant Therapy: A Case Report.Surgical case reports · 2025Article
- A Rare and Rapidly Progressive Case of Primary Esophageal Malignant Melanoma in an Elderly Patient.Cureus · 2024Article
- Rare malignant neoplasm of the esophagus: current status and future perspectives.Japanese journal of clinical oncology · 2024Review
- Primary esophageal malignant melanoma without recurrence after surgery and adjuvant therapy with nivolumab.International cancer conference journal · 2023Article
- Incidence and survival of patients with primary gastrointestinal melanoma: a population-based study.International journal of colorectal disease · 2023Article
- Primary malignant melanoma of the esophagus: A case report.World journal of clinical cases · 2023Article
- A CT-Based Radiomics Nomogram Model for Differentiating Primary Malignant Melanoma of the Esophagus from Esophageal Squamous Cell Carcinoma.BioMed research international · 2023Article
- Primary esophageal melanoma: a case report.Melanoma management · 2022Article
- A case of long-term survival treated with three metastasectomies and two subsequent adjuvant nivolumab therapies for recurrent malignant melanoma of the esophagus.Surgical case reports · 2022Article
- Clinicopathological characterization of ten patients with primary malignant melanoma of the esophagus and literature review.World journal of gastrointestinal oncology · 2022Article
- Primary malignant melanoma of the esophagus: differentiation from esophageal squamous cell carcinoma and leiomyoma using dynamic contrast-enhanced CT findings.Abdominal radiology (New York) · 2022Article
- Longitudinal genomic alternations and clonal dynamics analysis of primary malignant melanoma of the esophagus.Neoplasia (New York, N.Y.) · 2022Article
- The Thousand Faces of Malignant Melanoma: A Systematic Review of the Primary Malignant Melanoma of the Esophagus.Cancers · 2022Review
- Clinical characteristics and treatment outcomes of primary malignant melanoma of esophagus: a single center experience.BMC gastroenterology · 2022Article
- Article
- Primary malignant melanoma in gastroesophageal junction with 36 months' recurrence-free: a case report.AME case reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrimary malignant melanoma of the esophagus (PMME) is rare. Patients with advanced melanoma of esophageal origin tend to have lower response rates to traditional therapies than those with other melanomas. We report our experience of 12 patients with PMME administered PD-1 inhibitors.
methodsThis is a retrospective analysis of the clinical data of 76 patients with PMME who attended Peking University Cancer Hospital between January 2008 and September 2017. Objective response rates (ORRs) and progression-free survival (PFS) were assessed.
resultsThe 76 PMMEs were classified as unresectable or metastatic. The patients were allocated to three cohorts according to their treatment: chemotherapy (C: 46 patients), targeted therapy (T: 2 patients), and PD-1 inhibitors (IT: 12 patients). The PFS in the C cohort was three months with a limited ORR of 10.9%. In the IT cohort, seven patients (75.0%) achieved a partial response and three had stable disease for 4+ months. The median PFS in the IT cohort was not reached and the mean was 15.6 months, which was much longer than in cohort C (P < 0.001).
conclusionAlthough this cohort of patients was small, it is the largest series investigated thus far. To the best of our knowledge, this is the first report of the outcomes of advanced PMMEs treated with PD-1 inhibitors. Dramatic responses can occur in patients with advanced PMMEs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.